Importantly, the oral administration of CMC-AXT-NPs effectively suppressed the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, indicating that these nanoparticles had the ability to modulate the immune response associated with IBD. Here, IL6 is linked to inflammatory bowel disease.